Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung valve registry shows promise for emphysema patients

NCT ID NCT04517916

Disease control Sponsor: Pulmonx Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed French registry tracked 155 adults with severe emphysema or COPD who received Zephyr Valves, tiny devices placed in the lungs to help them work better. The goal was to see if the treatment safely improves breathing over 12 months. Researchers measured lung function and used CT scans to check for lung volume reduction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Zephyr Valve (a device placed in the lungs to reduce air trapping)
What this could lead to
If results are positive, this could support continued use of the Zephyr Valve as a safe and effective treatment for severe emphysema/COPD.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients, and risks like infection or valve movement exist.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

155 people

The number who actually took part.

Started

Jan 2021

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is an all-comers Registry. Physicians at participating study centers will invite consecutive patients who are prescribed Zephyr Valve treatment to participate in the Registry and allow data collection.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with emphysema (COPD Grade III and Grade IV) considered appropriate for the bronchoscopic lung volume reduction procedure by the physician. * Subjects who signed an Informed Consent Form to allow data collection. Exclusion Criteria: * Subjects determined to have collateral ventilation between the target(s) and ipsilateral lobe(s).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Emphysema or COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease pulmonary emphysema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Emphysema or COPD

Contacts and locations

Locations

  • Hôpital Arnaud de Villeneuve

    Montpellier, France

  • Hôpital Bichat

    Paris, France

  • Hôpital Calmette

    Lille, France

  • Hôpital Charles Nicolle

    Rouen, France

  • Hôpital Cochin

    Paris, France

  • Hôpital Dupuytren

    Limoges, France

  • Hôpital François Mitterrand

    Dijon, France

  • Hôpital La Cavale Blanche

    Brest, France

  • Hôpital Larrey

    Toulouse, France

  • Hôpital Nord

    Latronche, France

  • Hôpital Nord

    Saint-Etienne, France

  • Nouvel Hôpital Civil

    Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.